NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031210209

Registered date:28/07/2021

A Study of TAK-662 for Japanese Patients with Congenital Protein C Deficiency

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedCongenital Protein C Deficiency
Date of first enrollment07/09/2021
Target sample size5
Countries of recruitment
Study typeInterventional
Intervention(s)TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants.TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.

Outcome(s)

Primary Outcome1.PK Part: Protein C activity Level of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion Protein C is a vitamin K-dependent plasma protein and is an important component of the coagulation system. Protein C activity level was measured by chromogenic assays. Protein C activity level of TAK-662 was reported. 2.PK Part: Terminal Phase Elimination Half-life (t1/2) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion t1/2 of TAK-662 was reported. 3.PK Part: Incremental Recovery (IR) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion IR of TAK-662 was reported measured in terms of international unit per milliliter/ international unit per kilogram (IU/mL)/(IU/kg). 4.PK Part: Percentage of In-vivo Recovery (IVR) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, 36 hours post-infusion IVR corrected for plasma was determined using the formula: IVR (percentage [%])= (Maximum observed plasma concentration (Cmax) [IU/mL] - Concentration (C)pre-infusion [IU/mL]) * Plasma volume pre-infusion (PV) milliliter (mL)/ Dose (international unit [IU])*100 where Cmax was the observed Cmax value before baseline correction. IVR of TAK-662 measured in terms of percentage was reported. 5.PK Part: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion AUClast of TAK-662 was reported measured in terms of international unit*hour per milliliter (IU*h/ml). 6.PK Part: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion AUC0-infinity of TAK-662 was reported. 7.PK Part: Maximum Observed Plasma Concentration (Cmax) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion Cmax of TAK-662 was reported. 1.PK Part: Protein C activity Level of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion Protein C is a vitamin K-dependent plasma protein and is an important component of the coagulation system. Protein C activity level was measured by chromogenic assays. Protein C activity level of TAK-662 was reported. 2.PK Part: Terminal Phase Elimination Half-life (t1/2) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion t1/2 of TAK-662 was reported. 3.PK Part: Incremental Recovery (IR) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion IR of TAK-662 was reported measured in terms of international unit per milliliter/ international unit per kilogram (IU/mL)/(IU/kg). 4.PK Part: Percentage of In-vivo Recovery (IVR) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, 36 hours post-infusion IVR corrected for plasma was determined using the formula: IVR (percentage [%])= (Maximum observed plasma concentration (Cmax) [IU/mL] - Concentration (C)pre-infusion [IU/mL]) * Plasma volume pre-infusion (PV) milliliter (mL)/ Dose (international unit [IU])*100 where Cmax was the observed Cmax value before baseline correction. IVR of TAK-662 measured in terms of percentage was reported. 5.PK Part: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion AUClast of TAK-662 was reported measured in terms of international unit*hour per milliliter (IU*h/ml). 6.PK Part: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion AUC0-infinity of TAK-662 was reported. 7.PK Part: Maximum Observed Plasma Concentration (Cmax) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion Cmax of TAK-662 was reported. 8.PK Part: Time to Reach the Maximum Plasma Concentration (Tmax) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion Tmax of TAK-662 was reported. 8.PK Part: Time to Reach the Maximum Plasma Concentration (Tmax) of TAK-662 Time Frame: Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion Tmax of TAK-662 was reported.
Secondary Outcome1.Number of Participants with Treatment-Related Adverse Experiences (AEs) Time Frame: From start of study drug administration up to Day 7 A treatment-related AE was defined as an adverse event that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug was not able to be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, might also be responsible. Number of participants with treatment-related AEs as assessed by the Investigator were reported. 2.Extension Part: Treatment of Acute Episodes Rated by Efficacy Rating Scale Time Frame: From Day 1 of Extension part up to end of study (up to approximately 35 months) 3.Extension Part: Percentage of Participants Who Experience Surgical Episodes During Short-Term Prophylaxis Time Frame: From Day 1 of Extension part up to end of study (up to approximately 35 months) 4.Extension Part: Number of Episodes of PF and/or Thrombotic Episodes during Long-Term Prophylaxis Time Frame: From Day 1 of Extension part up to end of study (up to approximately 35 months)

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderBoth
Include criteriaPK Part: 1. Male and female participants with Japanese nationality. 2. A diagnosis of congenital protein C deficiency (homozygous or compound heterozygous). 3. Asymptomatic participant. 4. Oral anticoagulants allowed to be received. Extension part: 1. Participants who participated in the PK part of this study (TAK-662-1501). 2. Participant who are; a. Diagnosed with purpura fulminans (PF), coumarin-induced skin necrosis (CISN)/ warfarin-induced skin necrosis (WISN), and/or other acute thromboembolic episode for on-demand treatment only; b. Requiring treatment with TAK-662 for short-term prophylaxis for surgical procedures; c. Requiring treatment with TAK-662 for long-term prophylaxis.
Exclude criteriaPK Part: 1. Current or recurrent disease that could affect the action, or disposition of the investigational product (IP), or clinical or laboratory assessments. 2. A body weight less than 8 kg. 3. Serious liver dysfunction, judged by the investigator. 4. Any thrombosis within 2 weeks prior to administration of the IP. 5. Other investigational product than TAK-662 received within 60 days prior to the administration of the IP. 6. Current or relevant history of physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures. 7. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied, or could affect the action or disposition of the IP, or clinical or laboratory assessment. 8. Known or suspected intolerance or hypersensitivity to the IP, closely-related compounds, or any of the stated ingredients. 9. Known history of alcohol or other substance abuse within the last year. 10.Within 30 days prior to the first dose of IP, a participant has been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this sponsored study. Extension part: 1. New serious medical conditions which could affect participant's safety or treatment were observed during participation in the PK part of this study (TAK-662-1501).

Related Information

Contact

Public contact
Name Trial Information Contact for Clinical
Address 1-1, Doshomachi 4-chome, Chuo-ku, Osaka Osaka Japan 540-8645
Telephone +81-6-6204-2111
E-mail smb.Japanclinicalstudydisclosure@takeda.com
Affiliation Takeda Pharmaceutical Company Limited
Scientific contact
Name Atsushi Nishizawa
Address 1-1, Doshomachi 4-chome, Chuo-ku, Osaka Osaka Japan 540-8645
Telephone +81-6-6204-2111
E-mail smb.Japanclinicalstudydisclosure@takeda.com
Affiliation Takeda Pharmaceutical Company Limited